CAS 1033767-86-0

Formule : C17H15N5

InChI : InChI=1S/C17H15N5/c1-9-14(7-18)17(15(8-19)10(2)20-9)12-4-5-16-13(6-12)11(3)21-22-16/h4-6,17,20H,1-3H3,(H,21,22)

Code InChI : QKVFMAAIXZONRN-UHFFFAOYSA-N

SMILES : CC1=C2C=C(C=CC2=NN1)C3C(=C(NC(=C3C#N)C)C)C#N

BAY-474

CAS : 1033767-86-0

BAY-474

Formule : C₁₇H₁₅N₅

Degré de pureté : ≥98%

Masse moléculaire : 289.33

Ref: 54-BUP08692

2,6-Dimethyl-4-(3-methyl-1H-indazol-5-yl)-1,4-dihydropyridine-3,5-dicarbonitrile

CAS : 1033767-86-0

Formule : C₁₇H₁₅N₅

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 289.3345

Ref: IN-DA01KJXH

BAY-474

CAS : 1033767-86-0

BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe

Formule : C₁₇H₁₅N₅

Degré de pureté : 98.98%

Couleur et forme : Solid

Masse moléculaire : 289.3345

Ref: TM-T7900

BAY-474

CAS : 1033767-86-0

2,6-Dimethyl-4-(3-methyl-1H-indazol-5-yl)-1,4-dihydropyridine-3,5-dicarbonitrile

Formule : C₁₇H₁₅N₅

Degré de pureté : 99%

Masse moléculaire : 289.33

Ref: IN-DG01165701

BAY-474

CAS : 1033767-86-0

BAY-474 is a combination of two active compounds, vegfr and mapk inhibitors. It has been shown to be effective for the treatment of bladder cancer in vitro and in vivo. BAY-474 is administered intraperitoneally for prophylaxis purposes. BAY-474 may also be used for the treatment of other types of cancers that have a high incidence of vascular endothelial growth factor (VEGF) expression, such as nasal cancer. The drug is solvated with an organic solvent, which may help to stabilize the drug's activity and improve its pharmacokinetics.

Formule : C₁₇H₁₅N₅

Degré de pureté : Min. 95%

Masse moléculaire : 289.33 g/mol

Ref: 3D-IRB76786